Literature DB >> 9226055

Systemic effects of two nasally administered glucocorticosteroids.

J A Wihl1, K E Andersson, S A Johansson.   

Abstract

Two topical corticosteroids, budesonide (BUD) and beclomethasone dipropionate (BDP), both administered as suspensions in water, were investigated in healthy volunteers regarding influence on cortisol in plasma and urine (U-cortisol) after nasal application. In the first study, single doses of 200, 400, and 800 micrograms of BDP and BUD were given at 10:00 pm. In the second study, 100, 200, and 400 micrograms were given mornings and evenings for 4 days. In the single-dose study, none of the drugs or doses showed any significant influence on cortisol in plasma. However, U-cortisol decreased significantly after BUD 400 and 800 micrograms. In the multidose study, U-cortisol values were significantly reduced after all doses of BUD and the highest dose of BDP. The compounds tested showed different ability to cause measurable systemic effects after nasal application. The clinical implication is that the prescriber, when choosing a compound, should take the application site into consideration and should also be encouraged to find the lowest effective dose.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226055     DOI: 10.1111/j.1398-9995.1997.tb01040.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  4 in total

Review 1.  Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis.

Authors:  Rami Jean Salib; Peter Hugo Howarth
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  Safety of intranasal corticosteroid sprays during pregnancy: an updated review.

Authors:  Ahmed H Alhussien; Riyadh A Alhedaithy; Saad A Alsaleh
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-21       Impact factor: 2.503

3.  Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.

Authors:  P T Daley-Yates; A C Price; J R Sisson; A Pereira; N Dallow
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 4.  Safety of intranasal corticosteroids in acute rhinosinusitis.

Authors:  Pascal Demoly
Journal:  Am J Otolaryngol       Date:  2008-06-16       Impact factor: 1.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.